[{"orgOrder":0,"company":"Protara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Cell and Gene therapy","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"TARA-002","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Protara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Protara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Protara Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Protara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Cell and Gene therapy","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"TARA-002","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Protara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Protara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Protara Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Protara Therapeutics","sponsor":"Cowen","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Cell and Gene therapy","date":"September 2020","year":"2020","type":"Public Offering","leadProduct":"TARA-002","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Protara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Protara Therapeutics \/ Cowen","highestDevelopmentStatusID":"9","companyTruncated":"Protara Therapeutics \/ Cowen"},{"orgOrder":0,"company":"Protara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"TARA-002","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Protara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Protara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Protara Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Protara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Cell and Gene therapy","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"TARA-002","moa":"Th1","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Protara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Protara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Protara Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Protara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"TARA-002","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Protara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Instillation","sponsorNew":"Protara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Protara Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Protara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"TARA-002","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Protara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Instillation","sponsorNew":"Protara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Protara Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Protara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Cell and Gene therapy","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"TARA-002","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Protara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Protara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Protara Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Protara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"TARA-002","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Protara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Instillation","sponsorNew":"Protara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Protara Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Protara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"TARA-002","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Protara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Protara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Protara Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Protara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"TARA-002","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Protara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Protara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Protara Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Protara Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"April 2024","year":"2024","type":"Private Placement","leadProduct":"TARA-002","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Protara Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Liquid, Instillation","sponsorNew":"Protara Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"7","companyTruncated":"Protara Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Protara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Small molecule","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Choline Chloride","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Protara Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Protara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Protara Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Protara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"TARA-002","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Protara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"Protara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Protara Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Protara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"TARA-002","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Protara Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Protara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Protara Therapeutics \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals by Protara Therapeutics
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
